Showing 2701-2710 of 6036 results for "".
- Eye PCR to Present Poster Presentations on Fixoflex, a New Intraocular Ophthalmic Implant Designed to Hold an IOL Inside Capsular Baghttps://modernod.com/news/eye-pcr-to-present-poster-presentations-on-fixoflex-a-new-intraocular-ophthalmic-implant-designed-to-hold-an-iol-inside-capsular-bag/2481087/At the ESCRS meeting in Milan, Italy, Eye PCR will provide Poster Presentations on Fixoflex, a new intraocular ophthalmic implant designed to hold an IOL minimizing any decentration and tilt inside of the eye’s natural capsular bag. According to Amsterdam-based Eye PCR,
- Neurolens Raises $67 Million Investment to Develop New Products and Accelerate Adoptionhttps://modernod.com/news/neurolens-raises-67-million-investment-to-develop-new-products-and-accelerate-adoption/2481080/Neurolens announced completion of a $67 million financing to fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens. The financing was led by MVM Partners, with additional participation from Falcon Vision/KKR, Marshall Wac
- California Legislature Passes Optometric Surgery Billhttps://modernod.com/news/california-legislature-passes-optometric-surgery-bill/2481077/The California Legislature recently passed AC 2236, an optometric surgery bill that, if signed into law, would expand optometrists’ scope of practice in California to include some scalpel and
- New MaximEyes.com Software Designed to Simplify EHR Navigation and Patient Flowhttps://modernod.com/news/new-maximeyescom-software-designed-to-simplify-ehr-navigation-and-patient-flow/2481076/First Insight has introduced MaximEyes.com, which is desinged go allow eye care processionals to access data—anywhere, anytime, from any device—in a web browser or via a local server.
- Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-submits-new-drug-application-to-the-fda-for-tp-03-for-the-treatment-of-demodex-blepharitis/2481073/Tarsus Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis. Demodex blepharitis is a highly prevalent eyelid m
- Lensar Announces Application for Certification of the ALLY Adaptive Cataract Treatment System in the EUhttps://modernod.com/news/lensar-announces-application-for-certification-of-the-ally-adaptive-cataract-treatment-system-in-the-eu/2481069/Lensar announced the application for certification of the ALLY Adaptive Cataract Treatment System in the European Union. “Following the FDA clearance of ALLY in June 2022 and recent US commercial launch, this is another important step in our effort to bring ALLY to
- ESCRS Delegates Invited to Attend a ‘Cataract Surgery Virtual Reality (VR) Training Experience’https://modernod.com/news/escrs-delegates-invited-to-attend-a-cataract-surgery-virtual-reality-vr-training-experience/2481034/Haag-Stret is inviting ESCRS delegates to booth B86/B78 to attend a "Cataract Surgery Virtual Reality (VR) Training Experience," and witness some of the exciting features of the Haag-Streit Simulation
- First SBL-3 ClearView Multifocal Intraocular Lens Implanted in UShttps://modernod.com/news/first-sbl-3-clearview-multifocal-intraocular-lens-implanted-in-us/2481031/Lenstec announce that the first US commercial implantations of their newly FDA approved SBL-3 ClearView Multifocal IOL (MIOL) were performed by Jeff Whitsett, MD, of Whitsett Vision, Houston, Texas. The SBL-3 Clearview Multifocal is a next-generation presbyopia-
- First Patients Treated with Lensar's ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/first-patients-treated-with-lensars-ally-adaptive-cataract-treatment-system/2481029/Lensar announced the first commercial cases performed with the ALLY Adaptive Cataract Treatment System by Robert Weinstock, MD, at The Eye Institute of West Florida. Dr. Weinstock performed 15 laser-assisted cataract surgery cases following the recent installation of his ALLY Syste
- Opthea Announces Financing Deals for OPT-302 in Wet AMDhttps://modernod.com/news/opthea-announces-financing-deals-for-opt-302-in-wet-amd/2481027/Opthea announced two financing deals aimed at advancing OPT-302, a drug candidate for wet age-related macular degeneration (AMD). Opthea announced a nondilutive financing transaction for up to $170 million from investment funds working with Launch Therapeutics to finance and advance the